

Andrea Matucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6565161/publications.pdf>

Version: 2024-02-01

38
papers

1,390
citations

361413

20
h-index

330143

37
g-index

40
all docs

40
docs citations

40
times ranked

2318
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 11-34.	2.4	235
2	Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?. <i>Respiratory Research</i> , 2018, 19, 113.	3.6	139
3	Acute infusion reactions induced by monoclonal antibody therapy. <i>Expert Review of Clinical Immunology</i> , 2011, 7, 55-63.	3.0	108
4	Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2011, 11, 262-268.	2.3	61
5	Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. <i>Clinical and Experimental Allergy</i> , 2013, 43, n/a-n/a.	2.9	61
6	Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab. <i>International Archives of Allergy and Immunology</i> , 2012, 159, 321-326.	2.1	59
7	Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2575-2581.e2.	3.8	48
8	Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 31, 123-129.	2.6	47
9	Eosinophils, the IL-5/IL-5R α axis, and the biologic effects of benralizumab in severe asthma. <i>Respiratory Medicine</i> , 2019, 160, 105819.	2.9	46
10	High Serum \hat{I}^2 -Lactams Specific/Total IgE Ratio Is Associated with Immediate Reactions to \hat{I}^2 -Lactams Antibiotics. <i>PLoS ONE</i> , 2015, 10, e0121857.	2.5	44
11	Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study. <i>Clinical Drug Investigation</i> , 2015, 35, 179-185.	2.2	43
12	Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 946-952.	1.2	34
13	Cellular and Humoral Immune Responses During Tuberculosis Infection: Useful Knowledge in the Era of Biological Agents. <i>Journal of rheumatology Supplement, The</i> , 2014, 91, 17-23.	2.2	34
14	The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review. <i>Respiratory Research</i> , 2018, 19, 154.	3.6	33
15	COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 871-874.	5.7	33
16	Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis. <i>Allergy, Asthma and Immunology Research</i> , 2020, 12, 885.	2.9	29
17	Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 422-432.	3.8	28
18	Detection by Flow Cytometry of ESAT-6- and PPD-Specific Circulating CD4+ T Lymphocytes as a Diagnostic Tool for Tuberculosis. <i>International Archives of Allergy and Immunology</i> , 2007, 143, 1-9.	2.1	27

#	ARTICLE	IF	CITATIONS
19	Asthma and Chronic Rhinosinusitis: How Similar Are They in Pathogenesis and Treatment Responses?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3340.	4.1	27
20	The emerging role of type 2 inflammation in asthma. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 63-71.	3.0	26
21	Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. <i>Internal and Emergency Medicine</i> , 2012, 7, 77-79.	2.0	24
22	Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 55-61.	2.4	20
23	Assays and Strategies for Immunogenicity Assessment of Biological Agents. <i>Drug Development Research</i> , 2014, 75, S4-6.	2.9	19
24	An overview on safety of monoclonal antibodies. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2016, 16, 576-581.	2.3	18
25	The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 2065-2072.e2.	3.8	18
26	Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 3-10.	2.4	15
27	How the immune system responds to therapeutic biological agents. <i>Journal of International Medical Research</i> , 2016, 44, 38-42.	1.0	13
28	IL-10â€œProducing Infliximab-Specific T Cells Regulate the Antidrug T Cell Response in Exposed Patients. <i>Journal of Immunology</i> , 2017, 199, 1283-1289.	0.8	13
29	Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study. <i>Angiology</i> , 2018, 69, 763-769.	1.8	13
30	Self-administration of omalizumab: why not? A literature review and expert opinion. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 499-507.	3.1	12
31	T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis. <i>Frontiers in Immunology</i> , 2019, 9, 3113.	4.8	10
32	Effect of dupilumab treatment in a severe asthma patient with EGPA. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3824-3825.	3.8	10
33	The percentage of patients achieving complete remission of urticaria increases with repeated courses of treatment. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 339-340.	3.8	9
34	The safety of monoclonal antibodies in asthma. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1087-1095.	2.4	8
35	Hypersensitivity reactions to biologics used in rheumatology. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1263-1271.	3.0	8
36	Anaphylactic reactions to biological drugs. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2020, 20, 346-351.	2.3	7

#	ARTICLE	IF	CITATIONS
37	Immunogenicity-unwanted immune responses to biological drugs “ can we predict them?. Expert Review of Clinical Pharmacology, 2021, 14, 47-53.	3.1	6
38	Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience. Journal of Asthma, 2023, 60, 158-166.	1.7	5